{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+Disorders&page=54", "query": { "condition": "Skin Disorders", "page": 54 }, "page_size": 10 }, "pagination": { "page": 54, "page_size": 10, "total_count": 16130, "total_pages": 1613, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+Disorders&page=55&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+Disorders&page=53&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-05T08:05:09.995Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00105976", "title": "Efficacy Study of MM-093 in Rheumatoid Arthritis Patients on Methotrexate (MTX)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "MM-093", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merrimack Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 260, "start_date": "2005-02", "completion_date": null, "has_results": false, "last_update_posted_date": "2008-07-11", "last_synced_at": "2026-11-05T08:05:09.995Z", "location_count": 38, "location_summary": "Birmingham, Alabama • Montgomery, Alabama • Paradise Valley, Arizona + 33 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Paradise Valley", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00105976" }, { "nct_id": "NCT03827876", "title": "Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "Enstilar 0.005%-0.064% Topical Foam", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Psoriasis Treatment Center of Central New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2019-01-16", "completion_date": "2019-12-15", "has_results": false, "last_update_posted_date": "2019-02-04", "last_synced_at": "2026-11-05T08:05:09.995Z", "location_count": 1, "location_summary": "East Windsor, New Jersey", "locations": [ { "city": "East Windsor", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03827876" }, { "nct_id": "NCT00295893", "title": "Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 121, "start_date": "2005-09-27", "completion_date": "2027-07-16", "has_results": true, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-11-05T08:05:09.995Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00295893" }, { "nct_id": "NCT00424684", "title": "Comparison of the Quantiferon®-TB GOLD (in Tube) Assay With Tuberculin Skin Testing for Detecting Latent Tuberculosis Infection in Patients With Chronic Liver Disease Being Evaluated for or Awaiting Liver Transplantation", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Chronic Liver Disease", "TB" ], "interventions": [ { "name": "collection of blood sample", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "University of Pittsburgh", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2007-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2020-05-07", "last_synced_at": "2026-11-05T08:05:09.995Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00424684" }, { "nct_id": "NCT03200847", "title": "Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Stage IV Melanoma", "Stage III Melanoma", "Advanced Melanoma" ], "interventions": [ { "name": "Pembrolizumab with All-Trans Retinoic Acid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 26, "start_date": "2017-10-31", "completion_date": "2022-10-19", "has_results": true, "last_update_posted_date": "2024-10-01", "last_synced_at": "2026-11-05T08:05:09.995Z", "location_count": 2, "location_summary": "Aurora, Colorado • Fort Collins, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Fort Collins", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03200847" }, { "nct_id": "NCT04140526", "title": "Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer", "Advanced Solid Tumor", "Metastatic Melanoma", "Metastatic Head and Neck Carcinoma", "Metastatic Renal Cell Carcinoma", "Metastatic Colorectal Cancer", "Sarcomas", "Metastatic Prostate Cancer", "Ovarian Cancer", "Small Cell Lung Cancer", "Metastatic Breast Cancer", "Pancreas Cancer", "Gastric Cancer", "Esophageal Cancer", "Gastroesophageal Junction Adenocarcinoma", "Cervical Cancer", "Adenoid Cystic Carcinoma", "Salivary Gland Cancer", "Urothelial Carcinoma" ], "interventions": [ { "name": "ONC-392", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OncoC4, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 733, "start_date": "2020-09-16", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-11-05T08:05:09.995Z", "location_count": 33, "location_summary": "Springdale, Arkansas • Davis, California • Downey, California + 27 more", "locations": [ { "city": "Springdale", "state": "Arkansas" }, { "city": "Davis", "state": "California" }, { "city": "Downey", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04140526" }, { "nct_id": "NCT06074315", "title": "Evaluation of the Effectiveness of Nail Genesis DLSO Product for Onychomycosis", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Distal Lateral Subungual Onychomycosis", "Onychomycosis" ], "interventions": [ { "name": "Nail Genesis DLSO Product", "type": "DEVICE" }, { "name": "Nail Genesis DLSO Product (vehicle only)", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Nail Genesis LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 338, "start_date": "2023-10-01", "completion_date": "2025-01", "has_results": false, "last_update_posted_date": "2023-12-08", "last_synced_at": "2026-11-05T08:05:09.995Z", "location_count": 10, "location_summary": "Fayetteville, Arkansas • Montclair, California • Sacramento, California + 7 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Montclair", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Bernardino", "state": "California" }, { "city": "South Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06074315" }, { "nct_id": "NCT02947685", "title": "Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HER-2 Positive Breast Cancer", "Estrogen Receptor Positive Breast Cancer" ], "interventions": [ { "name": "palbociclib", "type": "DRUG" }, { "name": "trastuzumab", "type": "DRUG" }, { "name": "pertuzumab", "type": "DRUG" }, { "name": "letrozole", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alliance Foundation Trials, LLC.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 518, "start_date": "2017-06-21", "completion_date": "2030-12-31", "has_results": true, "last_update_posted_date": "2026-10-22", "last_synced_at": "2026-11-05T08:05:09.995Z", "location_count": 35, "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Clearwater, Florida + 30 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Clearwater", "state": "Florida" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02947685" }, { "nct_id": "NCT03271021", "title": "A Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 in the Treatment of Moderate-to-Severe Acne Vulgaris", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acne Vulgaris" ], "interventions": [ { "name": "FMX101", "type": "DRUG" }, { "name": "Vehicle Foam", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vyne Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "9 Years", "maximum_age": null, "sex": "ALL", "summary": "9 Years and older" }, "enrollment_count": 1488, "start_date": "2017-07-17", "completion_date": "2018-09-04", "has_results": true, "last_update_posted_date": "2022-01-18", "last_synced_at": "2026-11-05T08:05:09.995Z", "location_count": 98, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Bryant, Arkansas + 83 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Bryant", "state": "Arkansas" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03271021" }, { "nct_id": "NCT06388304", "title": "THRIVE Study: Positive Affect Training for Endocrine Therapy Medication Adherence", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer", "DCIS" ], "interventions": [ { "name": "THRIVE Online PAT Program", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Joanna Arch", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "FEMALE", "summary": "21 Years and older · Female only" }, "enrollment_count": 39, "start_date": "2024-03-12", "completion_date": "2025-04-18", "has_results": false, "last_update_posted_date": "2026-01-21", "last_synced_at": "2026-11-05T08:05:09.995Z", "location_count": 1, "location_summary": "Boulder, Colorado", "locations": [ { "city": "Boulder", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06388304" } ] }